Kornimate/medical-research-clean huggingface dataset:
the efficacy of patients with moderate to severe atopic dermatitis treated with chinese herbal medicine

Conditions: Atopic Dermatitis

Summary: conduct a clinical trial of integration of chinese and western medicine to evaluate whether the association of traditional chinese medicine therapy has a remission effect on atopic dermatitis, and to explore the remission of lesions after an association of chinese herbal medicine, and the correlation of syndrome differentiation types before and after treatment with chinese and western medicine, with a view to better understand the efficacy of atopic dermatitis in the treatment of the same disease in traditional chinese medicine, and provide another option for patients with atopic dermatitis.

this examination will be posted at taipei veterans general hospital to recruit 24 participants who meet the inclusion criteria of atopic dermatitis to do the study. after participants agreeing to the clinical study and signing the consent form, the investigators are going to separate them into the a group (12 participants) and the b group (12 participants). the tests are going to take a total of 14 weeks. participants need to pass the international diagnostic criteria hannifin and rajka to be determined as patients with atopic dermatitis. after, participants need test by scoring atopic dermatitis index (scorad) to be determined as mild to moderate atopic dermatitis and accept the wang qi traditional chinese medical constitutional scale (tcmcs), dermatological quality of life index (dlqi) score or children's skin disease quality of life index (cdlqi) score, routine blood tests, liver and kidney function tests, immunological markers associated with atopic dermatitis diagnosis of (eosinophils count, ecp, and ige), tongue diagnosis, and pulse diagnosis. after the collection of data is completed, the investigators will be analyzing the data by spss version 21 as a two-paired t-test, anova statistical method, and p \<0.05 as a significant result.

Eligibility criteria:
inclusion criteria: * 6 years old to 30 years old. * diagnosis as an atopic dermatitis patient. * the score of the scorad is over 20. (moderate to severe atopic dermatitis) exclusion criteria: * secondary bacterial infections * received oral or intravenous steroid treatment, anti-biotics, phototherapy, or other immunosuppressive therapies in the previous 2 months. * received chinese herbal medicine treatment or acupuncture. * pregnant woman or current breastfeeding. * who had catastrophes illness now or in the past must be avoided. * can not sign informed consent or can not communicate with the researcher. * abnormal liver enzymes. * abnormal kidney function tests (1.5 times higher than the upper normal limit)

Keywords: atopic dermatits chinese herbal medicine integrative medicine
an open-label dose-escalation study to evaluate xmab24306 as a single agent and in combination with atezolizumab in participants with locally advanced or metastatic solid tumors

Conditions: Solid Tumors

Summary: this study will evaluate the safety, tolerability, pharmacokinetics, and activity of xmab24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.


Eligibility criteria:
key general inclusion criteria * eastern cooperative oncology group (ecog) performance status of 0 or 1 * life expectancy \>/= 12 weeks * adequate hematologic and end-organ function * for participants receiving therapeutic anticoagulation: stable anticoagulant regimen * negative serum pregnancy test for women of childbearing potential * histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy * measurable disease per response evaluation criteria in solid tumors (recist) v1.1 * availability of representative tumor specimens key general exclusion criteria * pregnant or breastfeeding, or intending to become pregnant during the study * significant cardiovascular disease * current treatment with medications that prolong the qt interval * known clinically significant liver disease * poorly controlled type 2 diabetes mellitus * symptomatic, untreated, or actively progressing cns metastases * history of leptomeningeal disease * history of malignancy other than disease under study within 3 years prior to screening * active or history of autoimmune disease or immune deficiency * active tuberculosis, hepatitis b, hepatitis c, or known/suspected epstein barr virus infection * positive for hiv infection * prior allogeneic stem cell or solid organ transplantation
the effects of enoximone in acute exacerbation copd

Conditions: COPD Exacerbation; Enoximone; Phosphodiesterase Inhibitor

Summary: introduction: the pharmacodynamic properties of enoximone could be beneficial for patients with an acute exacerbation copd (ae-copd). this research will focus on patients suffering of a severe ae-copd and the bronchodilatory and inotropic effects of lower doses of enoximone. the main objective of the pilot study is to investigate if there is a bronchodilatory effect of enoximone in patients with ae-copd. secondary objective is to investigate a dose responsiveness in a range between 0.5 and 1.5 mg/kg enoximone. methods: the study design is a prospective interventional non-randomized clinical series study involving patients admitted and intubated at the intensive care unit (icu) with an ae-copd. patients will receive three times a dose of 0.5 mg/kg enoximone with a one-hour-interval. the primary objective is a reduction in auto-positive end-expiratory pressure (peep) after enoximone compared to baseline. a dose-titration will test for dose dependency. secondary objectives are a reduction in ventilator pressures, a reduction in pulmonary artery pressures and an increase in cardiac output.

ventilator will be set during the study period at volume controle, 6 ml/kg, 5 peep and a respiratory rate of 15 bpm with an i:e-ratio of 1:2. salbutamol/ipratropium bromide and magnesium sulphate will be administered at baseline (t=0h) and measurements will be made for an hour. at t=1h the first dose of 0.5 mg/kg enoximone will be administered and will be repeated at t=2h and t=3h. ventilator derived variables will be obtained every fifteen minutes and echocardiography, arterial and central venous bloodgas analyses every hour until t=6h.

Eligibility criteria:
inclusion criteria: * patients with an ae-copd for which intubation occurred within 24 hours before enrolment. exclusion criteria: * patients with known asthma or interstitial lung disease (ild) * known neurodegenerative diseases such as amyotrophic lateral sclerosis (als), multiple sclerosis (ms), guillain-barre and dementia * hypertrophic obstructive cardiomyopathy (hocm) * severe aortic stenosis with aortic valve area \< 1cm2 * known ventricular arrhythmias * severe kidney disorders with glomerular filtration rate (gfr) \< 30 * severe liver insufficiency with spontaneous pt/inr \> 1.5 * pregnancy * lactation * high dose-diuretics use (daily dose of \>480 mg furosemide)
study on the progress of breast cancer cases in males and the assessment of relapse risk

Conditions: Breast Cancer, Male

Summary: an observational, other designs (od) post-marketing, multicenter study, which will obtain retrospective data from male patients diagnosed with invasive breast cancer between 2000 and 2019 in the medical oncology departments of hospitals that are associated with spanish breast cancer research group (geicam) (using information obtained from patient medical histories).

one of the objectives of this project is to ensure representativeness of the cases referred to. accordingly, participating sites agree to enroll in the study male patients who were diagnosed with breast cancer in the period between 2000 and 2019.

Eligibility criteria:
inclusion criteria: * male patients diagnosed with primary invasive breast carcinoma between the years 2000-2019, and who have been treated and/or followed up in the medical oncology departments of participating sites. * the enrollment of patients who died is allowed. exclusion criteria: * male patients who do not wish to participate in the study for any reason.

Keywords: breast cancer in males observational gene sequencing
research on the development and clinical evaluation of biomimetic abutments

Conditions: Tooth Loss

Summary: this study aims to evaluate the clinical effectiveness of biomimetic abutments in implant restoration.

the biomimetic healing abutments were placed during the second-stage surgery, and the biomimetic prosthetic abutments were used to complete the implant restoration. to assess soft tissues, digital models were collected in stl files at five time points: before the second-stage surgery, before the implant impression, immediately after restoration, six months after restoration, and 12 months after restoration. these models were analyzed using 3d software for model matching and measurement based on cbct, focusing on the changes on soft tissue height, width, and volume. hard tissue evaluation was conducted through periapical radiographs taken at three time points: immediately after restoration, six months after restoration, and 12 months after restoration. additionally, general clinical conditions were assessed at the same three time points, evaluating parameters such as food impaction, plaque index, and gingival index.

Eligibility criteria:
inclusion criteria: * aged between 25 and 65 years old * had one single edentulous site * implant embedded healed and required secondary surgery to expose * good treatment compliance and could attend follow-up appointment regularly exclusion criteria: * soft tissue grafting was needed * severe acute or chronic periodontitis * heavy smoking habit (\> 10 cigarettes/day) * poor oral hygiene
study on the immunogenicity and tolerability of influsplit ssw® 2005/2006 in children aged 6 - 13 years

Conditions: Influenza

Summary: the study will evaluate the immune response and the tolerability of the influenza vaccine administered in children aged 6-13 years old.


Eligibility criteria:
inclusion criteria: * healthy children or children with an increased health risk due to an underlying chronic disease-such as chronic airways diseases (including asthma), chronic cardiovascular, hepatic and renal diseases as well as diabetes and other metabolic diseases-aged between 6 and 13 years. * all subjects must not have received a prior influenza vaccination. * all subjects must not have had a prior influenza disease. exclusion criteria: * use of any study or unlicensed medications/ vaccine other than the study vaccine within 30 days of the vaccination and/or during the study period. * acute illness at the start of the study. * acute, clinically significant pulmonary, cardiovascular abnormalities or abnormalities of the hepatic or renal function. * known allergic reactions which might be caused by the ingredients of the vaccine. * girls post-menarche: pregnancy or positive pregnancy-test * multiple sclerosis or congenital or acquired immunodeficiencies.
treatment of wegener's granulomatosis with cyclophosphamide

Conditions: Vasculitis; Wegener's Granulomatosis

Summary: the purpose of this protocol is to continue to treat patients with wegener's granulomatosis who have already entered the study, and to treat new patients. the investigators will attempt to correlate the clinical response with specific immunosuppressive effects of drug administration. the investigators are accumulating data on the optimal duration and side effects of therapy.

the purpose of the protocol is to continue to treat patients with wegener's granulomatosis who have already entered the study, and to treat new patients. the investigators will attempt to correlate the clinical response with specific immunosuppressive effects of drug administration. the investigators are accumulating data on the optimal duration and side effects of therapy. age range: greater than 1 year

Eligibility criteria:
patients greater than 1 year of age with the clinical and pathological diagnosis of wg whose illness presents a risk of permanent disability or death. examples of processes that impart risk of permanent disability or death include: peripheral and central nervous system disease, cardiac involvement, glomerulonephritis, and vascular comprise of gastrointestinal organs. no women who are pregnant or intend to become pregnant. no patients who have known malignancies. patients must be hiv negative.

Keywords: vasculitis prednisone granuloma wegener's granulomatosis cyclophosphamide renal biopsy
nottingham osteoarthritis biomarker study 2011

Conditions: Osteoarthritis

Summary: osteoarthritis is by far the most common joint condition and the single largest cause of disability in the older population. the investigators still have a poor understanding of the nature of osteoarthritis and factors that influence its development and progression. identification of biochemical markers that relate to cartilage loss, bony overgrowth and other features that occur with osteoarthritis will advance our understanding. over the last 5 years analytical methods have developed to measure a range of different biomarkers. this pilot study will use these analytical methods to measure biomarker levels in joint fluid, urine and blood of 50 participants with osteoarthritis (oa) and 50 healthy volunteers. this study will provide novel pilot data on the changes in the composition of the synovial fluid, urine and blood in patients with oa. apart from being a key target site for oa, the knee is a suitable joint for study because of its accessibility to clinical assessment, joint aspiration and imaging.


Eligibility criteria:
inclusion criteria: all participants: * be able to provide written informed consent * aged 30 and over knee oa patients: • radiographic signs of oa - that is definite joint space narrowing plus osteophyte in at least one compartment of the knee normal controls: * no knee pain * no clinical or radiographic changes of knee oa
study to investigate the effect of formoterol vs salmeterol on small airways physiological parameters in copd patients

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: this is a crossover study to investigate the effect of formoterol versus salmeterol on small airways physiological parameters in copd patients.

a single-centre, double-blind, double-dummy, randomised, crossover study to investigate the effect of formoterol hfa-pmdi versus salmeterol hfa-pmdi on small airways physiological parameters in copd patients.

Eligibility criteria:
inclusion criteria: * patients with a clinical diagnosis of copd * post bronchodilator fev1 between 30% and 80% predicted values at screening * post-bronchodilator fev1/fvc \< 0.7 exclusion criteria: * positive fev1 reversibility test: fev1 change greater than 200 ml and 12% * history of another medical condition contraindicating participation in the study * clinical evidence of heart failure
air versus sf6 for descemet's membrane endothelial keratoplasty (dmek)

Conditions: Fuchs' Endothelial Dystrophy; Bullous Keratopathy

Summary: this blinded, randomized study compares the use of air and sulfur hexaflouride (sf6) tamponade in descemet membrane endothelial keratoplasty.


Eligibility criteria:
inclusion criteria: - eligible for dmek surgey exclusion criteria: related to ocular health * re-dmek or prior penetrating keratoplasty * ocular hypertension resistant to topical medication * previous vitrectomy * minimally invasive glaucoma devices * aphakia * anterior chamber or iris claw lens * implantable collamer lens (icl) * clinically significant corneal scarring * central corneal thickness \>750 µm * bcva \< 0.1 related to general health * not able to give informed consent * inability to position correctly due to organic or psychological condition. related to surgical procedure * graft diameter \>9 mm or \< 7mm * graft central endothelial cell count \< 2000 cells/mm2 * graft unfolding duration \>1 hour * graft morphology grade 4-5 * significant graft decentration (graft contour not visible in microscope) * significant presence of descemet remnants in the graft-host interface * presence of inward folds * graft 'stroma-surface' placed facing away from recipient stroma

Keywords: intraocular gas positioning dmek endothelial keratoplasty
management of metastatic breast cancer in clinical practice - retrospective study

Conditions: Metastatic Breast Cancer

Summary: the purpose of this study is to evaluate the incidence rate of progression of disease, to describe the diagnostic and clinical management in patients with metastatic breast cancer in the clinical practice in bulgaria.

a retrospective cohort study on therapeutic management of metastatic breast cancer in clinical practice in bulgaria

Eligibility criteria:
inclusion criteria: * new diagnosis of breast cancer according to icd-10 with confirmed metastasis * confirmed diagnosis between 1st july 2010 and 30th june 2011. * female patient managed for her disease at the same setting where final diagnosis of mbc was performed. exclusion criteria: * history of concurrent or other primary malignancies (except curatively resected non-melanoma skin cancer or in situ cervical cancer).

Keywords: metastatic breast cancer, retrospective study, disease progression, clinical management
assessing the burden of respiratory syncytial virus (rsv)

Conditions: Respiratory Syncytial Virus (RSV) Infection; Acute Lower Respiratory Tract Infections; Bronchiolitis; Pneumonia; Chronic Respiratory Conditions

Summary: this study examines the impact of respiratory syncytial virus (rsv) on people of all ages, from infants to the elderly. it uses hospital records collected between january 2018 and december 2024 to understand: * how often does rsv occur * who is most at risk * the long-term and financial effects of rsv

this study is designed to analyze the impact of respiratory syncytial virus (rsv) across different age groups. it focuses on how often rsv occurs, who is most at risk, and its long-term and financial effects. the study uses existing hospital records from seha facilities between january 2018 and december 2024. this is a retrospective observational study, meaning no new tests or treatments are given. researchers look at medical records from past patients who were diagnosed with rsv. anonymized data is collected from seha's electronic medical records (emr) and laboratory systems. only patients with confirmed rsv infections are included.

Eligibility criteria:
inclusion criteria: * patients of all ages with a confirmed diagnosis of rsv infection * patients admitted to a seha hospital or healthcare facility between january 2018 and december 2024 * patients with documented data in the seha electronic medical record (emr) system exclusion criteria: * patients with suspected rsv infection that is not laboratory-confirmed * patients without sufficient data in the seha emr system

Keywords: respiratory syncytial virus rsv rsv infection rsv in infants rsv in adults rsv hospitalization rsv epidemiology rsv burden rsv risk factors retrospective study observational study icu admissions rsv mortality rsv cost analysis rsv complications asthma and rsv bronchiolitis pneumonia recurrent wheezing rsv surveillance rsv-related comorbidities
a study of the first-line treatment of patients with newly diagnosed transplant-ineligible multiple myeloma in spain

Conditions: Multiple Myeloma

Summary: this is an observational, post-authorization, retrospective, multicenter study (pas-od) that will be conducted in approximately 20 centers in spain. in all cases, only data recorded prior to the date of study start will be collected to ensure its retrospective nature, thus reflecting real clinical practice, avoiding any influence on the physician's clinical practice.


Eligibility criteria:
inclusion criteria: * patients aged ≥ 18 years * patients with newly diagnosed mm who were not suitable candidates for asct who started anti-myeloma treatment between 2012 and 2016, inclusive. * patients who give informed consent before data collection begins. exclusion criteria: * patients who participated in a clinical trial for first-line treatment of mm during the study period. * patients who are alive, but do not give their ic. * patients with mm who did not receive treatment.

Keywords: transplant multiple myeloma spain
a comparison between deep sclerectomy and trabeculectomy

Conditions: Glaucoma

Summary: patients affected by medically uncontrolled open angle glaucoma will be randomised to either a non penetrating procedure (deep sclerectomy) or conventional trabeculectomy. the longterm efficacy (i.e. iop w/out therapy) and safety (i.e. visual acuity, visual field stability and co-morbidities) will be evaluated.

prospective 7-year randomised investigator -masked clinical trial 79 eyes (79 patients) enrolled randomised to surgery by pex and previous pilocarpine use deep sclerectomy n = 41 trabeculectomy n = 38 estimated ds : te success = 1:3 10% attrition ; power = 90%, alpha = 5% methods and evaluation of outcomes: 1. iop: average of the two highest readings of the iop phasing (6 readings) 2. va: logmar (etdrs chart) 3. lens: locsii (slit lamp classification), worsening = one step progression confirmed at two visits study visits: every 4 months

Eligibility criteria:
inclusion criteria: * angle wide open * age \> 65 yrs * iop \> 23 and \< 30 mmhg (average of the two highest readings of the daily iop phasing) * topical beta blocker in fellow eye * at least two medications in use + previous alt * md \< 20 db (hfa 24-2 full threshold) * locsii \< c1-n1-p0

Keywords: glaucoma surgery non penetrating procedures cataract
laparoscopic cholecystectomy in idiopathic pancreatitis

Conditions: Idiopathic Pancreatitis

Summary: the causes of acute pancreatitis in finland are alcohol overuse (60%), cholecystolithiasis (20%) and idiopathic (i.e. etiology unknown)(20%). acute pancreatitis may recur in over half of cases and may be fatal in severe cases in 30%. majority of idiopathic pancreatitis are caused by microlithiasis in gall bladder. the purpose of this randomized study is to prevent recurrence of idiopathic pancreatitis by performing laparoscopic cholecystectomy compared to non-operative group in 2 years follow-up of patients.

etiologic investigations include serum amylase, lipase, triglyceride and calcium determination, as well as abdominal ultrasound scanning. alcohol consumption is asked by using who audit test. after etiology of acute pancreatitis has been confirmed as idiopathic, 100 patients are randomized to laparoscopic cholecystectomy and 100 patients to follow-up of 2 years. five to seven finnish university and main central hospitals are participating the study.

Eligibility criteria:
inclusion criteria: * idiopathic pancreatitis exclusion criteria: * age \< 18 years old * patients' refusal * high operative risks * alcohol overuse

Keywords: recurrence of idiopathic pancreatitis laparoscopic cholecystectomy etiology of pancreatitis